Catalogue Number: AB00726-23.0-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | CD194; CKR-4; CCR-4; CCR4; K5-5 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 200 ug |
| Host name: | Rabbit |
| Clone: | KW-0761 (Mogamulizumab) |
| Isotype: | IgG |
| Immunogen: | This antibody was prepared by humanization of a mouse anti-CCR4 mAb. |
| Application: | Depl |
CCR4
P51679
1233
Purified
Recombinant Monoclonal
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
The clinically used format of this antibody (which underwent additional de-fucosylation to increase antibody-dependent cellular cytotoxicity (ADCC)), has significant clinical activity in heavily pretreated patients with mycosis fungoides and Sezary syndrome, and is associated with an overall response rate of 36.8% and a median duration of response of 10.4 months (Duvic et al, 2014). It was shown to CCR4-expressing cells by antibody-dependent, cell-mediated cytotoxicity (ADCC). Therapeutically, this results in a dual mechanism of action; in addition to directly targeting malignant T cells over-expressing CCR4, this antibody also depletes T reg cells, an important therapeutic target in human cancers. This antibody is well-tolerated, and administration does not appear to trigger clinically significant autoimmune complications in phase 1/2 trials (Duvic et al, 2014). This antibody has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma, and is in clinical trials for solid cancers. For the avoidance of doubt - the material produced by Absolute Antibody has not been de-fucosylated.
This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.